Heart disease remains a leading cause of mortality worldwide, with heart failure accounting for 13 percent of global deaths. The inability of the human heart to regenerate lost muscle cells after birth has driven the exploration of cell-based therapies. Over the past two decades, significant
Beckman Coulter Life Sciences, a subsidiary of Danaher Corporation, has announced the launch of the Cydem VT Automated Clone Screening System, an innovative platform designed to transform the world of drug discovery through advanced laboratory automation and innovation. This groundbreaking
Recent findings have shed light on the pivotal role of fibroblastic reticular cells (FRCs) in enhancing the immune response within lung cancer tumors, particularly non-small cell lung cancer (NSCLC). These specialized cells create environments that bolster T-cell activity, potentiating anti-tumor
Roche is making a bold move in the field of allogeneic cell therapy with its recent acquisition of Poseida Therapeutics, a San Diego-based biotech firm. This $1 billion upfront deal underscores Roche's commitment to expanding its portfolio in cell and gene therapies, particularly targeting
Gene therapy has made remarkable strides in recent years, with 20 approved indications in the United States and a record number of approvals in 2023. Investigational trials are rapidly increasing across various diseases, including hemophilia B, sickle cell disease, and Duchenne muscular dystrophy.
Recent advancements in the field of cancer immunotherapy have unveiled an exciting discovery that involves the molecule MR1 and vitamin B6. Researchers at Monash University Biomedicine Discovery Institute, in collaboration with the University of Melbourne, have found that MR1 can bind to a form of
